Alzheimer’s disease (AD) is an age-associated neurodegenerative disease that is reaching epidemic proportions as a result of the aging of the world’s population. It is likely that the most effective treatment for AD will need to be administrated before cognitive symptoms occur, necessitating a biomarker for the early stages of AD. Novel high-resolution MRI technologies with the capability to characterize the individual beta-amyloid plaque through the whole brain is highly desirable.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: